首页> 美国卫生研究院文献>Toxicological Research >Anti-Diabetic Effects of Dung Beetle Glycosaminoglycan on db Mice and Gene Expression Profiling
【2h】

Anti-Diabetic Effects of Dung Beetle Glycosaminoglycan on db Mice and Gene Expression Profiling

机译:甲虫糖胺聚糖对db小鼠的抗糖尿病作用及基因表达谱分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Anti-diabetes activity of Catharsius molossus (Ca, a type of dung beetle) glycosaminoglycan (G) was evaluated to reduce glucose, creatinine kinase, triglyceride and free fatty acid levels in db mice. Diabetic mice in six groups were administrated intraperitoneally: Db heterozygous (Normal), Db homozygous (CON), Heuchys sanguinea glycosaminoglycan (HEG, 5 mg/kg), dung beetle glycosaminoglycan (CaG, 5 mg/kg), bumblebee (Bombus ignitus) queen glycosaminoglycan (IQG, 5 mg/kg) and metformin (10 mg/kg), for 1 month. Biochemical analyses in the serum were evaluated to determine their anti-diabetic and anti-inflammatory actions in db mice after 1 month treatment with HEG, CaG or IQG treatments. Blood glucose level was decreased by treatment with CaG. CaG produced significant anti-diabetic actions by inhiting creatinine kinase and alkaline phosphatase levels. As diabetic parameters, serum glucose level, total cholesterol and triglyceride were significantly decreased in CaG5-treated group compared to the controls. Dung beetle glycosaminoglycan, compared to the control, could be a potential therapeutic agent with anti-diabetic activity in diabetic mice. CaG5-treated group, compared to the control, showed the up-regulation of 48 genes including mitochondrial yen coded tRNA lysine (mt-TK), cytochrome P450, family 8/2, subfamily b, polypeptide 1 (Cyp8b1), and down-regulation of 79 genes including S100 calcium binding protein A9 (S100a9) and immunoglobulin kappa chain complex (Igk), and 3-hydroxy-3-methylglutaryl-CoenzymeAsynthase1 (Hmgcs1). Moreover, mitochondrial thymidine kinase (mt-TK), was up-regulated, and calgranulin A (S100a9) were down-regulated by CaG5 treatment, indicating a potential therapeutic use for anti-diabetic agent.
机译:评估了Catharsius molossus(一种,类甲虫)糖胺聚糖(G)的抗糖尿病活性,以降低db小鼠的葡萄糖,肌酐激酶,甘油三酸酯和游离脂肪酸的水平。对六组糖尿病小鼠进行腹膜内给药:Db杂合子(正常),Db纯合子(CON),Heuchys血红糖胺聚糖(HEG,5 mg / kg),甲虫糖胺聚糖(CaG,5 mg / kg),大黄蜂(Bombus ignitus)女王糖胺聚糖(IQG,5 mg / kg)和二甲双胍(10 mg / kg),1个月。在用HEG,CaG或IQG处理1个月后,评估血清中的生化分析以确定它们在db小鼠中的抗糖尿病和抗炎作用。用CaG治疗可降低血糖水平。 CaG通过破坏肌酸酐激酶和碱性磷酸酶水平产生了显着的抗糖尿病作用。作为糖尿病参数,与对照组相比,CaG5治疗组的血清葡萄糖水平,总胆固醇和甘油三酯显着降低。与对照相比,粪甲虫糖胺聚糖可能是糖尿病小鼠中具有抗糖尿病活性的潜在治疗剂。与对照组相比,CaG5处理组显示48个基因的上调,包括线粒体日元编码的tRNA赖氨酸(mt-TK),细胞色素P450,家族8/2,亚家族b,多肽1(Cyp8b1)和调控79个基因,包括S100钙结合蛋白A9(S100a9)和免疫球蛋白kappa链复合物(Igk),以及3-羟基-3-甲基戊二酰辅酶Asynthase1(Hmgcs1)。此外,线粒体胸苷激酶(mt-TK)上调,而钙调蛋白A(S100a9)通过CaG5处理下调,表明抗糖尿病药的潜在治疗用途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号